SARS-CoV-2 and hepatitis

J Gastrointestin Liver Dis. 2020 Sep 9;29(3):473-475. doi: 10.15403/jgld-2747.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Alanine Transaminase / blood*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Aspartate Aminotransferases / blood*
  • Betacoronavirus* / isolation & purification
  • Betacoronavirus* / pathogenicity
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Testing
  • Chemical and Drug Induced Liver Injury* / blood
  • Chemical and Drug Induced Liver Injury* / diagnosis
  • Chemical and Drug Induced Liver Injury* / etiology
  • Chloroquine* / administration & dosage
  • Chloroquine* / adverse effects
  • Clinical Laboratory Techniques / methods
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / physiopathology
  • Diagnosis, Differential
  • Drug Combinations
  • Hepatitis, Viral, Human* / blood
  • Hepatitis, Viral, Human* / diagnosis
  • Hepatitis, Viral, Human* / etiology
  • Humans
  • Liver / pathology
  • Liver Function Tests / methods
  • Lopinavir* / administration & dosage
  • Lopinavir* / adverse effects
  • Male
  • Middle Aged
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / physiopathology
  • Ritonavir* / administration & dosage
  • Ritonavir* / adverse effects
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Chloroquine
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Ritonavir